Schisandrin A inhibits the development of OA through inhibition of mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways [52] and is known to exhibit potent anticancer activity in colon cancer cells [53]. Here, NFKB1 is linked to colonic neoplasm.